SY
SYK.US Stryker Corporation
- Market cap
- USD 121B
- P/E
- 33.8x
- P/B
- 5.04x
- ROE
- 15.8%
- Dividend yield
- 1.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SYK.US undervalued?
Graham numberSYK.US trades 175.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stryker Corporation fundamental analysis
No fundamental analysis for Stryker Corporation yet.
Stryker Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial in…
Full company profileStryker Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stryker Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.3B | 12.4B | 13.6B | 14.9B | 14.4B | 17.1B | 18.4B | 20.5B | 22.6B | 25.1B | 25.5B |
| Gross Profit | 7.25B | 7.90B | 8.60B | 9.38B | 8.75B | 10.7B | 11.0B | 12.5B | 14.5B | 16.1B | 16.7B |
| Operating Income | 2.58B | 2.77B | 3.10B | 3.39B | 3.03B | 3.76B | 3.73B | 4.28B | 3.69B | 4.89B | 4.84B |
| EBITDA | 2.70B | 2.95B | 3.34B | 3.63B | 3.08B | 3.61B | 4.02B | 5.06B | 6.01B | 6.31B | 6.12B |
| Net Income | 1.65B | 1.02B | 3.55B | 2.08B | 1.60B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B | 3.70B |
| EPS | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | 5.22 | 6.17 | 8.25 | 7.76 | 8.49 | 9.61 |
| Balance Sheet | |||||||||||
| Total Assets | 20.4B | 22.2B | 27.2B | 30.2B | 34.3B | 34.6B | 36.9B | 39.9B | 43.0B | 47.8B | 47.2B |
| Total Liabilities | 10.9B | 12.2B | 15.5B | 17.4B | 21.2B | 19.8B | 20.3B | 21.3B | 22.3B | 25.4B | 23.8B |
| Shareholders' Equity | 9.55B | 9.99B | 11.7B | 12.8B | 13.1B | 14.9B | 16.6B | 18.6B | 20.6B | 22.4B | 23.5B |
| Cash & Short-term Investments | 3.38B | 2.79B | 3.70B | 4.43B | 3.02B | 3.02B | 1.93B | 3.05B | 4.40B | 4.10B | 3.27B |
| Total Debt | 6.91B | 7.22B | 9.86B | 11.1B | 14.0B | 12.5B | 13.5B | 13.5B | 14.1B | 16.4B | 15.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.92B | 1.56B | 2.61B | 2.19B | 3.28B | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B | 4.40B |
| Capital Expenditure | 490M | 598M | 572M | 649M | 487M | 525M | 588M | 575M | 755M | 761M | 807M |
| Free Cash Flow | 1.43B | 961M | 2.04B | 1.54B | 2.79B | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B | 3.60B |
| Ratios | |||||||||||
| ROE | 17.2% | 10.2% | 30.3% | 16.3% | 12.2% | 13.4% | 14.2% | 17.0% | 14.5% | 14.5% | 15.8% |
| ROA | 8.1% | 4.6% | 13.0% | 6.9% | 4.7% | 5.8% | 6.4% | 7.9% | 7.0% | 6.8% | 7.8% |
| Net Profit Margin | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% | 14.5% |
| Debt to Equity | 0.72x | 0.72x | 0.84x | 0.87x | 1.07x | 0.84x | 0.81x | 0.73x | 0.68x | 0.73x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stryker Corporation dividends
- Dividend yield
- 1.06%
- Forward dividend
- 3.52 USD
- Payout ratio
- 39.6%
- Ex-dividend date
- Sep 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.28B | 3.36 | 39.6% |
| 2024 | USD 1.22B | 3.16 | 40.7% |
| 2023 | USD 1.14B | 2.97 | 36.0% |
| 2022 | USD 1.05B | 2.75 | 44.6% |
| 2021 | USD 950M | 2.48 | 47.6% |
| 2020 | USD 863M | 2.27 | 54.0% |
| 2019 | USD 778M | 2.05 | 37.3% |
| 2018 | USD 703M | 1.85 | 19.8% |
| 2017 | USD 636M | 1.67 | 62.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 17, 2004.
Who owns Stryker Corporation
- Insiders 5.46%
- Institutions 82.34%
- Public & others 12.21%
- Shares outstanding 381M
- Free float 346M
Top funds holding SYK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 11.0M | 2.88% | -0.06% | Sep 2026 |
| Vanguard 500 Index Investor | 9.17M | 2.41% | +0.01% | Sep 2026 |
| iShares Core S&P 500 ETF | 4.65M | 1.22% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 4.54M | 1.19% | +1.28% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 4.26M | 1.12% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 3.29M | 0.86% | +99.49% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 2.55M | 0.67% | +0.88% | Oct 2026 |
| Vanguard Dividend Growth Inv | 2.19M | 0.57% | -4.41% | Sep 2026 |
| Vanguard Wellington Inv | 2.09M | 0.55% | -2.55% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 1.97M | 0.52% | +1.11% | Sep 2026 |
| Vanguard Institutional Index I | 1.85M | 0.49% | +0.12% | Sep 2026 |
| Parnassus Core Equity Investor | 1.45M | 0.38% | -11.53% | Sep 2026 |
| Vanguard Equity-Income Inv | 1.44M | 0.38% | 0.00% | Sep 2026 |
| AllianceBernstein US L/C Growth Eqty MF | 1.39M | 0.36% | -1.32% | Jun 2026 |
| American Funds Cptl Wld Gr&Inc A | 1.29M | 0.34% | 0.00% | Sep 2026 |
| Vanguard Health Care Inv | 1.09M | 0.29% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 1.05M | 0.28% | +0.13% | Sep 2026 |
| Franklin Rising Dividends A | 1.03M | 0.27% | -22.51% | Sep 2026 |
| State Street® SPDR® Port S&P 500® ETF | 971K | 0.26% | -0.07% | Oct 2026 |
| JPMorgan Equity Premium Income ETF | 960K | 0.25% | -0.02% | Oct 2026 |
Top institutions holding SYK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 27.4M | 7.20% | -0.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 22.5M | 5.92% | +0.69% | Jun 2026 |
| JPMorgan Chase & Co | 17.3M | 4.53% | +10.67% | Jun 2026 |
| State Street Corp | 15.5M | 4.08% | +1.19% | Jun 2026 |
| Greenleaf Trust | 15.2M | 4.00% | -4.45% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 11.9M | 3.13% | +18.72% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.17M | 2.15% | -1.93% | Jun 2026 |
| Wellington Management Company LLP | 8.17M | 2.15% | +0.56% | Jun 2026 |
| Geode Capital Management, LLC | 7.82M | 2.05% | +0.92% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.96M | 1.57% | -5.35% | Jun 2026 |
| AllianceBernstein L.P. | 4.93M | 1.29% | -18.60% | Jun 2026 |
| NORGES BANK | 4.89M | 1.29% | -5.63% | Jun 2026 |
| Bank of America Corp | 4.46M | 1.17% | +8.42% | Jun 2026 |
| Bank of New York Mellon Corp | 3.55M | 0.93% | -10.22% | Jun 2026 |
| Royal Bank of Canada | 3.48M | 0.91% | +6.18% | Jun 2026 |
| Northern Trust Corp | 3.33M | 0.87% | +0.70% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 3.28M | 0.86% | +110.99% | Jun 2026 |
| Ameriprise Financial Inc | 3.27M | 0.86% | +132.64% | Jun 2026 |
| First Western Trust Bank | 3.02M | 0.79% | -0.07% | Jun 2026 |
| Fundsmith LLP | 2.91M | 0.77% | -4.82% | Jun 2026 |
Stryker Corporation company profile
- Company name
- Stryker Corporation
- Ticker
- SYK.US
- Exchange
- USA Stocks
- Listed since
- Feb 1, 1988
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 56,000
- Fiscal year end
- December
- Address
- 1941 Stryker Way, Portage, MI, United States, 49002
- Phone
- (269) 385-2600
- Website
- stryker.com
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stryker Corporation management
10- Mr. Kevin A. LoboChairman & CEO · born 1965
- Mr. Spencer S. StilesPresident & COO · born 1976
- Mr. Preston W. WellsVP & CFO · born 1977
- Mr. Viju S. MenonGroup President of Global Quality & Operations · born 1968
- Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology · born 1974
- Ms. Emily BaculikVP, Chief Accounting Officer & Corporate Controller · born 1980
- Mr. Robert C. CohenCTO and VP of Global R&D - Joint Replacement
- Ms. Debra S. KingVP and Chief Digital & Information Officer · born 1972
- Mr. Nick MeadVice President of Investor Relations
- Mr. Robert S. FletcherVP & Chief Legal Officer · born 1971